Mohit Narang

831 total citations
64 papers, 526 citations indexed

About

Mohit Narang is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Mohit Narang has authored 64 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 28 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Mohit Narang's work include Multiple Myeloma Research and Treatments (46 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (15 papers). Mohit Narang is often cited by papers focused on Multiple Myeloma Research and Treatments (46 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (15 papers). Mohit Narang collaborates with scholars based in United States, United Kingdom and Switzerland. Mohit Narang's co-authors include Robert M. Rifkin, Rafat Abonour, Kathleen Toomey, James W. Hardin, Shankar Srinivasan, Amani Kitali, Howard R. Terebelo, Cristina Gasparetto, Brian G.M. Durie and Sundar Jagannath and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mohit Narang

61 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohit Narang United States 12 435 298 272 74 64 64 526
Elias Kiwan United States 8 591 1.4× 443 1.5× 379 1.4× 76 1.0× 28 0.4× 12 765
David Martínez‐Cuadrón Spain 13 325 0.7× 214 0.7× 164 0.6× 82 1.1× 108 1.7× 56 537
Ernesto Pérez Persona Spain 9 462 1.1× 302 1.0× 235 0.9× 149 2.0× 23 0.4× 24 580
Marcello Rotta United States 13 631 1.5× 314 1.1× 295 1.1× 63 0.9× 59 0.9× 29 756
Dolores Carrera Spain 5 514 1.2× 269 0.9× 239 0.9× 49 0.7× 73 1.1× 7 584
Ivan Pašić Canada 12 238 0.5× 164 0.6× 121 0.4× 47 0.6× 85 1.3× 80 514
Timothy M. Schmidt United States 9 476 1.1× 397 1.3× 268 1.0× 68 0.9× 13 0.2× 29 579
Sangeetha Venugopal United States 13 336 0.8× 254 0.9× 105 0.4× 162 2.2× 55 0.9× 44 583
Morgan Mace United States 4 244 0.6× 158 0.5× 84 0.3× 76 1.0× 58 0.9× 8 351
Shivlal Pandey United States 4 913 2.1× 634 2.1× 560 2.1× 130 1.8× 31 0.5× 6 1.0k

Countries citing papers authored by Mohit Narang

Since Specialization
Citations

This map shows the geographic impact of Mohit Narang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohit Narang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohit Narang more than expected).

Fields of papers citing papers by Mohit Narang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohit Narang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohit Narang. The network helps show where Mohit Narang may publish in the future.

Co-authorship network of co-authors of Mohit Narang

This figure shows the co-authorship network connecting the top 25 collaborators of Mohit Narang. A scholar is included among the top collaborators of Mohit Narang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohit Narang. Mohit Narang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ailawadhi, Sikander, Hans C. Lee, James Omel, et al.. (2024). Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry. Blood Cancer Journal. 14(1). 198–198. 2 indexed citations
3.
Castillo, Jorge J., Edwin Kingsley, Mohit Narang, et al.. (2023). Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States. SHILAP Revista de lepidopterología. 4(1). 301–304. 3 indexed citations
4.
Lee, Hans C., Karthik Ramasamy, Katja Weisel, et al.. (2022). Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clinical Lymphoma Myeloma & Leukemia. 23(2). 112–122. 6 indexed citations
5.
Rifkin, Robert M., Jeffrey Crawford, Reshma Mahtani, et al.. (2022). A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices. Supportive Care in Cancer. 30(10). 7913–7922. 9 indexed citations
6.
7.
Gasparetto, Cristina, Sundar Jagannath, Robert M. Rifkin, et al.. (2021). Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clinical Lymphoma Myeloma & Leukemia. 22(3). 149–157. 10 indexed citations
8.
Ailawadhi, Sikander, Kathleen Toomey, James W. Hardin, et al.. (2020). Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.. Journal of Clinical Oncology. 38(15_suppl). 8518–8518. 2 indexed citations
9.
Jagannath, Sundar, Robert M. Rifkin, Cristina Gasparetto, et al.. (2019). Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. Clinical Lymphoma Myeloma & Leukemia. 20(5). 272–276. 11 indexed citations
10.
Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2018). Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Advances. 2(13). 1608–1615. 29 indexed citations
11.
Durie, BG, Sundar Jagannath, Mohit Narang, et al.. (2018). Health-Related Quality of Life Assessments Predict Relapse or Death in Patients with Newly Diagnosed Multiple Myeloma (MM): Results from the Connect® MM Registry. Value in Health. 21. S6–S6. 1 indexed citations
12.
13.
Abonour, Rafat, Lynne I. Wagner, Brian G.M. Durie, et al.. (2018). Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Annals of Hematology. 97(12). 2425–2436. 29 indexed citations
14.
Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2018). Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). Clinical Lymphoma Myeloma & Leukemia. 18(7). 480–485.e3. 24 indexed citations
15.
Shah, Jatin J., Rafat Abonour, Christina Gasparetto, et al.. (2017). Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clinical Lymphoma Myeloma & Leukemia. 17(9). 575–583.e2. 62 indexed citations
16.
Kaur, Navjot, Jaspreet Jain, Ankit Kumar, et al.. (2017). Chikungunya outbreak in Delhi, India, 2016: report on coinfection status and comorbid conditions in patients. New Microbes and New Infections. 20. 39–42. 40 indexed citations
17.
18.
Grinblatt, David L., Mikkael A. Sekeres, Rami S. Komrokji, et al.. (2014). Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA®registry. Leukemia & lymphoma. 56(4). 887–895. 25 indexed citations
19.
Grinblatt, David L., et al.. (2011). PSY72 VARIATION BY AGE IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS INITIATING TREATMENT FOR MYELODYSPLASTIC SYNDROMES. Value in Health. 14(3). A72–A72. 1 indexed citations
20.
Narang, Mohit, et al.. (2003). Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). American Journal of Hematology. 74(4). 263–267. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elias Kiwan Breakdown of academic impact, for papers by David Martínez‐Cuadrón Breakdown of academic impact, for papers by Ernesto Pérez Persona Breakdown of academic impact, for papers by Marcello Rotta Breakdown of academic impact, for papers by Dolores Carrera Breakdown of academic impact, for papers by Ivan Pašić Breakdown of academic impact, for papers by Timothy M. Schmidt Breakdown of academic impact, for papers by Sangeetha Venugopal Breakdown of academic impact, for papers by Morgan Mace Breakdown of academic impact, for papers by Shivlal Pandey
Rankless by CCL
2026